{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:37:19Z","timestamp":1777718239171,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2015R1A3A2066581"],"award-info":[{"award-number":["2015R1A3A2066581"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2015R1A3A2066581"],"award-info":[{"award-number":["2015R1A3A2066581"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-024-05535-2","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:24:32Z","timestamp":1738333472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ebastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1007","volume":"82","author":[{"given":"Seungyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Ji","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjin","family":"Rho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulagna","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyuk Wan","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Soon","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon-Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8152-9210","authenticated-orcid":false,"given":"Jaewhan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"5535_CR1","doi-asserted-by":"publisher","first-page":"710285","DOI":"10.3389\/fphys.2021.710285","volume":"12","author":"P Zhang","year":"2021","unstructured":"Zhang P et al (2021) Similarities and differences: a comparative review of the molecular mechanisms and effectors of NAFLD and AFLD. Front Physiol 12:710285. https:\/\/doi.org\/10.3389\/fphys.2021.710285","journal-title":"Front Physiol"},{"key":"5535_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-nutr-062220-105200","volume":"42","author":"L Rui","year":"2022","unstructured":"Rui L, Lin JD (2022) Reprogramming of hepatic metabolism and microenvironment in nonalcoholic steatohepatitis. Annu Rev Nutr 42:91\u2013113. https:\/\/doi.org\/10.1146\/annurev-nutr-062220-105200","journal-title":"Annu Rev Nutr"},{"key":"5535_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.025","author":"H Perazzo","year":"2023","unstructured":"Perazzo H, Pacheco AG, Griep RH, Collaborators, (2023) Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.025","journal-title":"J Hepatol"},{"key":"5535_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI (2021) Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184:2537\u20132564. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"key":"5535_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100723","volume":"3","author":"A Craciun","year":"2022","unstructured":"Craciun A, Cortez-Pinto H (2022) Alarming increase of NASH as cause of liver cancer. Cell Rep Med 3:100723. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100723","journal-title":"Cell Rep Med"},{"key":"5535_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan D, Surabattula R, Wang XY (2018) Determinants of fibrosis progression and regression in NASH. J Hepatol 68:238\u2013250. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.012","journal-title":"J Hepatol"},{"key":"5535_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41575-020-00365-6","volume":"18","author":"C Zhu","year":"2021","unstructured":"Zhu C, Tabas I, Schwabe RF, Pajvani UB (2021) Maladaptive regeneration\u2014the reawakening of developmental pathways in NASH and fibrosis. Nat Rev Gastroenterol Hepatol 18:131\u2013142. https:\/\/doi.org\/10.1038\/s41575-020-00365-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2809\u20132817","key":"5535_CR8","doi-asserted-by":"publisher","first-page":"e2828","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2019","unstructured":"Le MH et al (2019) Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 20(2809\u20132817):e2828. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5535_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"5535_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41575-019-0239-2","volume":"17","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G (2020) What\u2019s new in NAFLD pathogenesis, biomarkers and treatment? Nat Rev Gastroenterol Hepatol 17:70\u201371. https:\/\/doi.org\/10.1038\/s41575-019-0239-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5535_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ (2021) Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 18:373\u2013392. https:\/\/doi.org\/10.1038\/s41575-020-00408-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5535_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mce.2012.06.019","volume":"366","author":"HM O'Neill","year":"2013","unstructured":"O\u2019Neill HM, Holloway GP, Steinberg GR (2013) AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Mol Cell Endocrinol 366:135\u2013151. https:\/\/doi.org\/10.1016\/j.mce.2012.06.019","journal-title":"Mol Cell Endocrinol"},{"key":"5535_CR13","doi-asserted-by":"publisher","first-page":"970292","DOI":"10.3389\/fphys.2022.970292","volume":"13","author":"C Fang","year":"2022","unstructured":"Fang C et al (2022) The AMPK pathway in fatty liver disease. Front Physiol 13:970292. https:\/\/doi.org\/10.3389\/fphys.2022.970292","journal-title":"Front Physiol"},{"key":"5535_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ (2018) AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol 19:121\u2013135. https:\/\/doi.org\/10.1038\/nrm.2017.95","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5535_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jhep.2010.09.014","volume":"54","author":"M Foretz","year":"2011","unstructured":"Foretz M, Viollet B (2011) Regulation of hepatic metabolism by AMPK. J Hepatol 54:827\u2013829. https:\/\/doi.org\/10.1016\/j.jhep.2010.09.014","journal-title":"J Hepatol"},{"key":"5535_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","volume":"24","author":"GR Steinberg","year":"2023","unstructured":"Steinberg GR, Hardie DG (2023) New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol 24:255\u2013272. https:\/\/doi.org\/10.1038\/s41580-022-00547-x","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5535_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1172\/JCI16567","volume":"111","author":"B Viollet","year":"2003","unstructured":"Viollet B et al (2003) The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111:91\u201398. https:\/\/doi.org\/10.1172\/JCI16567","journal-title":"J Clin Invest"},{"key":"5535_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1126\/science.aah5582","volume":"357","author":"RW Myers","year":"2017","unstructured":"Myers RW et al (2017) Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 357:507\u2013511. https:\/\/doi.org\/10.1126\/science.aah5582","journal-title":"Science"},{"key":"5535_CR19","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/diabetes.51.7.2199","volume":"51","author":"ES Buhl","year":"2002","unstructured":"Buhl ES et al (2002) Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51:2199\u20132206. https:\/\/doi.org\/10.2337\/diabetes.51.7.2199","journal-title":"Diabetes"},{"key":"5535_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99114","author":"P Steneberg","year":"2018","unstructured":"Steneberg P et al (2018) PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.99114","journal-title":"JCI Insight"},{"key":"5535_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2006.05.005","volume":"3","author":"B Cool","year":"2006","unstructured":"Cool B et al (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403\u2013416. https:\/\/doi.org\/10.1016\/j.cmet.2006.05.005","journal-title":"Cell Metab"},{"key":"5535_CR22","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1038\/s41598-019-43228-0","volume":"9","author":"A Brandt","year":"2019","unstructured":"Brandt A et al (2019) Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. Sci Rep 9:6668. https:\/\/doi.org\/10.1038\/s41598-019-43228-0","journal-title":"Sci Rep"},{"key":"5535_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-021-01510-4","volume":"81","author":"S Dehnavi","year":"2021","unstructured":"Dehnavi S et al (2021) Targeting AMPK by Statins: A Potential Therapeutic Approach. Drugs 81:923\u2013933. https:\/\/doi.org\/10.1007\/s40265-021-01510-4","journal-title":"Drugs"},{"key":"5535_CR24","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1080\/15548627.2017.1356977","volume":"13","author":"SH Kim","year":"2017","unstructured":"Kim SH et al (2017) Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy 13:1767\u20131781. https:\/\/doi.org\/10.1080\/15548627.2017.1356977","journal-title":"Autophagy"},{"key":"5535_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","volume":"31","author":"C Jian","year":"2020","unstructured":"Jian C et al (2020) Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis. Cell Metab 31:892-908 e811. https:\/\/doi.org\/10.1016\/j.cmet.2020.04.011","journal-title":"Cell Metab"},{"key":"5535_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","volume":"28","author":"N Boudaba","year":"2018","unstructured":"Boudaba N et al (2018) AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development. EBioMedicine 28:194\u2013209. https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.008","journal-title":"EBioMedicine"},{"key":"5535_CR27","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.celrep.2017.03.011","volume":"18","author":"A Woods","year":"2017","unstructured":"Woods A et al (2017) Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep 18:3043\u20133051. https:\/\/doi.org\/10.1016\/j.celrep.2017.03.011","journal-title":"Cell Rep"},{"key":"5535_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2741\/3229","volume":"14","author":"B Viollet","year":"2009","unstructured":"Viollet B et al (2009) AMPK: lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) 14:19\u201344. https:\/\/doi.org\/10.2741\/3229","journal-title":"Front Biosci (Landmark Ed)"},{"key":"5535_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1126\/science.aay0542","volume":"367","author":"P Zhao","year":"2020","unstructured":"Zhao P et al (2020) An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367:652\u2013660. https:\/\/doi.org\/10.1126\/science.aay0542","journal-title":"Science"},{"key":"5535_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/hep4.1799","volume":"6","author":"P Gluais-Dagorn","year":"2022","unstructured":"Gluais-Dagorn P et al (2022) Direct AMPK activation corrects NASH in rodents through metabolic effects and direct action on inflammation and fibrogenesis. Hepatol Commun 6:101\u2013119. https:\/\/doi.org\/10.1002\/hep4.1799","journal-title":"Hepatol Commun"},{"key":"5535_CR31","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1172\/JCI69080","volume":"123","author":"JC Schisler","year":"2013","unstructured":"Schisler JC et al (2013) CHIP protects against cardiac pressure overload through regulation of AMPK. J Clin Invest 123:3588\u20133599. https:\/\/doi.org\/10.1172\/JCI69080","journal-title":"J Clin Invest"},{"key":"5535_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060512","author":"S-J Yang","year":"2021","unstructured":"Yang S-J, Jeon S, Baek JW, Lee KM, Park C-S (2021) Regulation of AMPK activity by CRBN is independent of the thalidomide-CRL4CRBN protein degradation axis. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph14060512","journal-title":"Pharmaceuticals"},{"key":"5535_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.molcel.2016.01.010","volume":"61","author":"M Deng","year":"2016","unstructured":"Deng M et al (2016) Deubiquitination and activation of AMPK by USP10. Mol Cell 61:614\u2013624. https:\/\/doi.org\/10.1016\/j.molcel.2016.01.010","journal-title":"Mol Cell"},{"key":"5535_CR34","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1038\/s41467-018-05721-4","volume":"9","author":"MS Lee","year":"2018","unstructured":"Lee MS et al (2018) Loss of the E3 ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome through AMPK activation. Nat Commun 9:3404. https:\/\/doi.org\/10.1038\/s41467-018-05721-4","journal-title":"Nat Commun"},{"key":"5535_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ebiom.2016.06.013","volume":"9","author":"AM Ellegaard","year":"2016","unstructured":"Ellegaard AM et al (2016) Repurposing cationic amphiphilic antihistamines for cancer treatment. EBioMedicine 9:130\u2013139. https:\/\/doi.org\/10.1016\/j.ebiom.2016.06.013","journal-title":"EBioMedicine"},{"key":"5535_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061610","author":"YC Liang","year":"2020","unstructured":"Liang YC et al (2020) The antihistamine deptropine induces hepatoma cell death through blocking autophagosome-lysosome fusion. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12061610","journal-title":"Cancers (Basel)"},{"key":"5535_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2021.11.007","volume":"40","author":"S Chen","year":"2022","unstructured":"Chen S, Luster AD (2022) Antihistamines for cancer immunotherapy: more than just treating allergies. Cancer Cell 40:9\u201311. https:\/\/doi.org\/10.1016\/j.ccell.2021.11.007","journal-title":"Cancer Cell"},{"key":"5535_CR38","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-20-0250","volume":"19","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) Antihistamine drug ebastine inhibits cancer growth by targeting polycomb group protein EZH2. Mol Cancer Ther 19:2023\u20132033. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0250","journal-title":"Mol Cancer Ther"},{"key":"5535_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00018-023-04760-5","volume":"80","author":"J Seo","year":"2023","unstructured":"Seo J et al (2023) Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase. Cell Mol Life Sci 80:132. https:\/\/doi.org\/10.1007\/s00018-023-04760-5","journal-title":"Cell Mol Life Sci"},{"key":"5535_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"Y Wen","year":"2021","unstructured":"Wen Y, Lambrecht J, Ju C, Tacke F (2021) Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 18:45\u201356. https:\/\/doi.org\/10.1038\/s41423-020-00558-8","journal-title":"Cell Mol Immunol"},{"key":"5535_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fimmu.2019.00893","volume":"10","author":"CJ Weston","year":"2019","unstructured":"Weston CJ, Zimmermann HW, Adams DH (2019) The role of myeloid-derived cells in the progression of liver disease. Front Immunol 10:893. https:\/\/doi.org\/10.3389\/fimmu.2019.00893","journal-title":"Front Immunol"},{"key":"5535_CR42","doi-asserted-by":"publisher","first-page":"165854","DOI":"10.1016\/j.bbadis.2020.165854","volume":"1866","author":"X Zhang","year":"2020","unstructured":"Zhang X et al (2020) The role of AMPKalpha2 in the HFD-induced nonalcoholic steatohepatitis. Biochim Biophys Acta Mol Basis Dis 1866:165854. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165854","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5535_CR43","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti G, Gross DA, Mingozzi F (2020) Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol 11:670. https:\/\/doi.org\/10.3389\/fimmu.2020.00670","journal-title":"Front Immunol"},{"key":"5535_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050785","author":"SS Issa","year":"2023","unstructured":"Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA (2023) Various AAV serotypes and their applications in gene therapy: an overview. Cells. https:\/\/doi.org\/10.3390\/cells12050785","journal-title":"Cells"},{"key":"5535_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.gendis.2023.02.010","volume":"11","author":"L Zhao","year":"2024","unstructured":"Zhao L et al (2024) Recombinant adeno-associated virus 8 vector in gene therapy: opportunities and challenges. Genes Dis 11:283\u2013293. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.010","journal-title":"Genes Dis"},{"key":"5535_CR46","doi-asserted-by":"publisher","first-page":"8S46","DOI":"10.1016\/S0929-693X(23)00227-0","volume":"30","author":"A Gardin","year":"2023","unstructured":"Gardin A, Ronzitti G (2023) Current limitations of gene therapy for rare pediatric diseases: lessons learned from clinical experience with AAV vectors. Arch Pediatr 30:8S46-48S52. https:\/\/doi.org\/10.1016\/S0929-693X(23)00227-0","journal-title":"Arch Pediatr"},{"key":"5535_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.celrep.2018.12.036","volume":"26","author":"D Garcia","year":"2019","unstructured":"Garcia D et al (2019) Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD. Cell Rep 26:192-208 e196. https:\/\/doi.org\/10.1016\/j.celrep.2018.12.036","journal-title":"Cell Rep"},{"key":"5535_CR48","doi-asserted-by":"publisher","first-page":"62780","DOI":"10.18632\/oncotarget.19376","volume":"8","author":"Z Liang","year":"2017","unstructured":"Liang Z et al (2017) AMPK: a novel target for treating hepatic fibrosis. Oncotarget 8:62780\u201362792. https:\/\/doi.org\/10.18632\/oncotarget.19376","journal-title":"Oncotarget"},{"key":"5535_CR49","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1158\/0008-5472.CAN-12-3876","volume":"73","author":"J Liang","year":"2013","unstructured":"Liang J, Mills GB (2013) AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73:2929\u20132935. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3876","journal-title":"Cancer Res"},{"key":"5535_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-cancerbio-030419-033619","volume":"4","author":"D Vara-Ciruelos","year":"2020","unstructured":"Vara-Ciruelos D, Dandapani M, Hardie DG (2020) AMP-activated protein kinase: friend or foe in cancer? Annual Rev Cancer Biol 4:1\u201316. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030419-033619","journal-title":"Annual Rev Cancer Biol"},{"key":"5535_CR51","doi-asserted-by":"publisher","first-page":"650165","DOI":"10.3389\/fonc.2021.650165","volume":"11","author":"L Gao","year":"2021","unstructured":"Gao L et al (2021) Proteome analysis of USP7 substrates revealed its role in melanoma through PI3K\/Akt\/FOXO and AMPK pathways. Front Oncol 11:650165. https:\/\/doi.org\/10.3389\/fonc.2021.650165","journal-title":"Front Oncol"},{"key":"5535_CR52","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2012.04.003","volume":"15","author":"NL Price","year":"2012","unstructured":"Price NL et al (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675\u2013690. https:\/\/doi.org\/10.1016\/j.cmet.2012.04.003","journal-title":"Cell Metab"},{"key":"5535_CR53","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","volume":"22","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE (2022) Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res 22:970. https:\/\/doi.org\/10.1186\/s12913-022-08272-z","journal-title":"BMC Health Serv Res"},{"key":"5535_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512339","author":"G Tandra","year":"2023","unstructured":"Tandra G et al (2023) Literature-based discovery predicts antihistamines are a promising repurposed adjuvant therapy for Parkinson\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241512339","journal-title":"Int J Mol Sci"},{"key":"5535_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13046-023-02914-8","volume":"43","author":"X Liu","year":"2024","unstructured":"Liu X et al (2024) Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer. J Exp Clin Cancer Res 43:5. https:\/\/doi.org\/10.1186\/s13046-023-02914-8","journal-title":"J Exp Clin Cancer Res"},{"key":"5535_CR56","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1046\/j.1365-2222.2003.01701.x","volume":"33","author":"M Nori","year":"2003","unstructured":"Nori M et al (2003) Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflammatory cytokines. Clin Exp Allergy 33:1544\u20131554. https:\/\/doi.org\/10.1046\/j.1365-2222.2003.01701.x","journal-title":"Clin Exp Allergy"},{"key":"5535_CR57","doi-asserted-by":"publisher","first-page":"12039","DOI":"10.1073\/pnas.0602216103","volume":"103","author":"TA Gray","year":"2006","unstructured":"Gray TA, Wilson A, Fortin PJ, Nicholls RD (2006) The putatively functional Mkrn1-p1 pseudogene is neither expressed nor imprinted, nor does it regulate its source gene in trans. Proc Natl Acad Sci U S A 103:12039\u201312044. https:\/\/doi.org\/10.1073\/pnas.0602216103","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05535-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05535-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05535-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:24:34Z","timestamp":1738333474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05535-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5535"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05535-2","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The Institutional Animal Care and Use Committees (IACUC) of the Laboratory Animal Research Center at Yonsei University conducted a comprehensive review and approved all procedures utilized in this study. (IACUC-A-201810-802-02).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"66"}}